Skip to content
Evigrade
CriticalAntifungal, triazole×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

The enzyme CYP3A4 metabolises ranolazine mainly, and CYP2D6 to a lesser extent. Ranolazine is also a substrate of P-glycoprotein (P-gp), and P-gp inhibitors may increase its absorption (ranolazine label, US Food and Drug Administration, FDA). The strong CYP3A4 inhibitor ketoconazole 200 mg twice daily raised the area under the concentration curve (AUC) of ranolazine 3.0–3.9-fold (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Itraconazole strongly inhibits CYP3A4 and also inhibits P-gp. It has not been studied directly with ranolazine but is likely to raise ranolazine levels (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ranolazine prolongs the corrected QT interval in a dose-related way, and higher levels raise the risk of dose-dependent adverse reactions such as nausea and dizziness (ranolazine SmPC, EMA).

Symptoms

As ranolazine levels rise, dizziness, nausea and vomiting become more frequent. Very high exposure has caused double vision, lethargy and fainting (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Ranolazine overdose has caused low blood pressure, QT prolongation, slow heart rate, myoclonic jerks, severe tremor, unsteady gait and incoordination, dizziness, nausea, vomiting, speech difficulty and hallucinations (ranolazine label, US Food and Drug Administration, FDA). Extreme overdose has been fatal (ranolazine FDA label). QT prolongation itself causes no symptoms and shows only on the electrocardiogram. Ventricular arrhythmias cause palpitations, dizziness and fainting.

Management

The combination is contraindicated in every document. The European Medicines Agency (EMA) summary of product characteristics (SmPC) for ranolazine contraindicates strong inhibitors of the enzyme CYP3A4 and names itraconazole among them (ranolazine SmPC, EMA). The US Food and Drug Administration (FDA) ranolazine label names itraconazole among the drugs that must not be taken with ranolazine (ranolazine label, FDA). The Spanish itraconazole SmPCs and the itraconazole FDA label list ranolazine among contraindicated drugs (itraconazole SmPCs and FDA label). Do not take ranolazine during itraconazole treatment or for two weeks after it ends (itraconazole Spanish SmPC and FDA label). After the last dose, itraconazole levels fall to almost undetectable in 7–14 days, and even more slowly in liver cirrhosis or with other CYP3A4 inhibitors (itraconazole SmPC). If ranolazine has already been taken with itraconazole, stop ranolazine, because the combination must not be used under any circumstances (itraconazole SmPC). In overdose, watch the patient closely and give symptomatic and supportive treatment (ranolazine SmPC, EMA). Continuous electrocardiogram (ECG) monitoring may be needed (ranolazine FDA label). Haemodialysis is unlikely to clear ranolazine because about 62% of it is bound to plasma proteins (ranolazine EMA SmPC and FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Itraconazole

Other interactions with Ranolazine